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ABSTRACT
Background: Oral rehydration solution (ORS) for treatment
of diarrhea relies on enhancement of small intestinal sodium
and fluid absorption to correct dehydration. Amylase-resistant
starch added to ORS significantly reduced the duration
and severity of diarrhea in adults with cholera, presumably
by generation of short-chain fatty acids in the colon
and enhancement of colonic sodium and fluid absorption.
The present study was initiated to determine whether addition
of amylase-resistant starch to standard World Health
Organization glucose-ORS (G-ORS) would reduce the dura-
tion of diarrhea and fecal fluid losses in children with
acute diarrhea.
Methods: One hundred eighty-three children (6 months to
3 years) with acute watery diarrhea were randomized to
receive either standard treatment with G-ORS or G-ORS with
additional amylase-resistant starch, HAMS (HAMS-ORS,
50 g/L). Stool weight and consistency were monitored serially
until development of formed stool or development of treat-
ment failure defined as either the need for unscheduled
intravenous fluid therapy or diarrhea longer than 72 hours.
Results: Five of the subjects were lost to follow up. In 178
remaining children (87 HAMS-ORS and 91 G-ORS) with
evaluable data, time from enrolment to last unformed stool
was significantly less in children receiving HAMS-ORS
(median, 6.75 hours; 95% confidence interval, 4.27Y9.22)
than in children treated with G-ORS (12.80 hours, 8.69Y16.91)
(P = 0.0292). Time to first formed stool was also significantly
shorter in children receiving HAMS-ORS (median, 18.25
hours; 95% confidence interval, 13.09Y23.41) compared with
children receiving G-ORS (median, 21.50 hours; 95% con-
fidence interval, 17.26Y25.74) (P = 0.0440). The total amount
of ORS consumed was similar in both groups. There was a
trend toward lower mean stool weight in first 24 hours (P =
0.0752) as well as total diarrheal stool weight (P = 0.0926) in
patients in the HAMS group compared with the G-ORS group.
Conclusion: In children with acute diarrhea, the addition of
amylase-resistant starch to glucose ORS significantly short-
ened duration of diarrhea compared with standard treatment.
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INTRODUCTION
Watery diarrhea continues to be a major cause of
childhood mortality in developing countries, with an
estimated 1.5 million children younger than 5 years dying
each year of diarrhea (1,2). This figure has greatly
reduced from approximately 5 million diarrheal deaths
annually 20 years ago (3), a phenomenon often attributed
to the utilization of oral rehydration solution (ORS) (3).
The introduction of ORS, hailed as one of the most
significant medical advances of the twentieth century,
allowed correction of dehydration and prevention of
mortality (4). The physiological basis for ORS is that
glucose-stimulated sodium and fluid absorption is not
inhibited by cyclic 3¶,5¶-adenosine monophosphate
(cAMP). However, the conventional glucose-based ORS
does not reduce duration or severity of diarrhea and may
in fact paradoxically increase fecal fluid losses (5). This
drawback associated with its usage has led to continuing
attempts to improve ORS composition to create a more
effective ORS or Bsuper-ORS.^
Bhan et al. (6) in 1994 compiled a summary of several
such attempts: rice-based ORS, maltodextrin- and amino
acid-containing ORS were not superior to glucose-based
ORS for acute noncholera diarrhea, provided that feeding
was promptly resumed after initial rehydration of the
child. A meta-analysis of 13 clinical trials suggested that
compared with glucose-ORS (G-ORS), rice-ORS reduced
stool output by about 18% in children with noncholera
diarrhea (7). Meta-analysis also suggested that most of
the effectiveness of rice- or other cereal-based ORS was
because of the low osmolality of the ORS used. Hypo-
osmolar ORS was particularly effective in the subgroup
without rotavirus. A meta-analysis of trials using reduced
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osmolarity ORS concluded that compared with World
Health Organization (WHO) standard ORS, hypo-
osmolar ORS was associated with fewer unscheduled
intravenous fluid infusions, lower stool volumes, and less
vomiting (8). The WHO recently recommended a change
in the composition of ORS to a low-sodium and low-
glucose solution (9).
All previous attempts at improving ORS have sought to
optimize small intestinal fluid absorption. In health, the
major function of the colon is to dehydrate colonic fluid
content, and this function becomes critical in diarrheal
disease. Thus, diarrhea has been interpreted as a failure
of colonic salvage of fluid (10). Short-chain fatty acids
(SCFAs) are the major colonic luminal anion with con-
centrations as high as 130 mmol/L and enhance sodium
absorption from both normal and secreting colon as a
result of the demonstrated failure of cAMP to inhibit
SCFA-stimulated sodium absorption (11,12). Preservation
of SCFA-linked sodium absorption in diarrhea may result
from SCFA stimulation of sodium absorption via sodium
hydrogen exchanger isoform 2 (NHE-2), which is not
inhibited by cAMP, whereas bicarbonate-linked sodium
absorption occurs only through NHE-3, which is inhibited
by cAMP (13). SCFAs also appear to inhibit chloride
secretion in the colon (14,15). SCFAs are formed in the
colon by the fermentation of nonabsorbed carbohydrates,
including amylase-resistant starch (ie, starch that is
relatively resistant to amylase digestion), by the anaerobic
bacterial flora (16). In a randomized clinical trial in adults
with cholera, the group that received amylase-resistant
(high-amylase maize, HAMS) starch had significantly
reduced stool volumes and duration of illness compared
with those patients treated with standard therapy consist-
ing of G-ORS and early refeeding (17).
Although cholera may be the most important dehy-
drating diarrhea in adults in developing countries,
children often have diarrhea due to causes other than
cholera. There have been 2 studies of the use of dietary
substances that are potentially fermented to SCFAs added
to ORS in the treatment of acute noncholera diarrhea in
children. In one study, partially hydrolyzed guar gum,
given as the SCFA precursor, significantly reduced the
duration of diarrhea in children with noncholera acute
diarrhea, compared with standard G-ORS (18). In another
recent study, a mixture of nondigestible carbohydrates
was used as the SCFA precursor but did not reduce either
the duration or volume of diarrhea in children with
noncholera diarrhea (19). The present study was designed
to assess the effect of HAMS-ORS compared with
standard WHO-ORS in the treatment of acute diarrhea
in children younger than 3 years.
METHODS
Consecutive children presenting to the outpatient clinics or
the pediatric emergency services of the Department of Child
Health, Christian Medical College and Hospital, Vellore,
India, were offered entry into the study if they fulfilled
inclusion and exclusion criteria and consented to the study
(Table 1). The study was conducted between January 2001 and
June 2004 by a team with prior experience in ORS trials.
Children were included if they were boys aged 6 months to
3 years and had diarrhea defined as more than 3 watery stools
in the past 24 hours with clinically detectable dehydration.
Children were excluded from the study if they had diarrhea of
duration longer than 7 days; blood and mucus in stool;
experienced a previous episode of diarrhea in the last 4 weeks;
concurrent pneumonia, meningitis, or infections requiring
antibiotics; or severe (grades III and IV) malnutrition.
Children with severe dehydration at presentation were
hydrated with intravenous fluids for 6 hours as per WHO
treatment plan C (20) and then included in the study if
intravenous fluids could be discontinued at this stage. Children
with severe dehydration who were not adequately hydrated at
the end of 6 hours of administration of intravenous fluids were
not included in the study.
Children were randomly allocated to 1 of 2 treatment groups.
The contents of the packets containing the formulations of 2
ORSs were made up to be dissolved in 200 mL of water. The
composition of G-ORS reflected the WHO recommendations at
the time the study was initiated in 2001 (Na, 90 mEq/L; K, 20
mEq/L; Cl, 80 mEq/L; citrate, 10 mmol/L; glucose, 111 mmol/L;
osmolarity, 311 mOsm/kg). HAMS-ORS packets contained 2
separate sachets, one with sufficient G-ORS (with the same
electrolyte, glucose concentration, and osmolarity as standard
WHO ORS) for 200 mL of water, and the other containing 10 g
HAMS. When the contents of the 2 sachets were dissolved in 200
mL of water it resulted in a cloudy suspension containing 50 g/L
of HAMS. Twenty packets of each ORS were randomly packed
in sealed opaque covers bearing serial study numbers. The study
numbers for each arm of the study were generated using a table
of random numbers in blocks of 40 patients, and the random-
ization code was retained by the Pharmacy Department. The
identity of the ORS used in individual patients was not revealed
TABLE 1. Baseline Characteristics of Children Recruited
into the Study
HAMS-ORS G-ORS
Total number of children 87 91
Number of children 12 months or older 36 32
Age (mo), mean T SE 12.0 T 0.6 11.5 T 0.6
Body weight (kg), mean T SE 8.2 T 0.2 8.2 T 0.2
Duration of diarrhea before
admission (h), mean T SE
46.5 T 3.1 52.1 T 2.5
Degree of dehydration at entry
Mild 49 43
Moderate 38 48
Treatment received before admission
Antibiotics 32 27
Intravenous fluids 28 31
Pathogen
Rotavirus 28 30
Vibrio cholerae 5 6
Other* 3 4
Numbers shown are those who were included in the final analysis.
*Other organisms identified include Cryptosporidium parvum in 2
children in the G-ORS group, Shigella boydii in 1 subject receiving
HAMS-ORS, and Giardia in 1 subject each receiving HAMS-ORS and
G-ORS. Pathogenic forms of Escherichia coli were not sought.
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to the clinicians caring for the patients or to the investigators
evaluating the patients. At admission into the study, each child
was assigned the next available serial number by the physician
recruiting the patient, and the nurse member of the team was
responsible for providing the cover with the ORS therapy
assigned for that specific child. The ORS was then mixed and
administered by 1 of the 4 nurses who were responsible for
supervising the study. Addition of HAMS to G-ORS created a
cloudy suspension that was physically distinctive in appearance
from G-ORS. Therefore, mixing and administration of the ORS
was performed solely by the study nurses and never in the
presence of the pediatricians responsible for clinical decisions or
for grading stool consistency. The study nurses did not determine
which specific study group any individual patient entered; this
was accomplished by providing sealed opaque covers (bearing
serial numbers in random order) with 1 of the 2 test ORSs. The
study pediatricians were not aware of the specific ORS treatment
that the child was receiving. However, the study was designed
such that 1 of 2 pediatricians was primarily responsible for
assessment of hydration and the clinical care of the child.
Because there was a possibility that this pediatrician might
accidentally become aware of the treatment that the patient was
receiving, the other pediatrician was responsible for assessing
stool consistency.
At entry, stool was examined by dark-field microscopy,
stool culture, and rotavirus enzyme-linked immunoassay.
Before the start of this study HAMS-ORS was administered
orally to 6 children with acute diarrhea and found to be well
tolerated. HAMS-ORS did not induce vomiting or significant
increase in diarrhea and was ingested by the children in the
quantities offered. HAMS-ORS was administered as a suspen-
sion without cooking because cooking was likely to alter the
amylase-resistant properties of the starch. Children were
admitted to a diarrhea ward where ORS was administered by
a team of study nurses in the quantities recommended in WHO
treatment plan B. Children in both treatment arms received
identical treatment, as per WHO guidelines, other than the
type of ORS. Oral intake of water was allowed ad libitum and
encouraged. Children were fed after the initial rehydration
period of 6 hours. Refeeding consisted of breast milk feeding
alternating with the ORS in infants, a weaning mixture
for children 6 to 12 months and a regular south Indian diet
(3 meals in 24 hours) in children older than 1 year. Blood tests
were performed as clinically indicated. Urine was collected
separate from stool using a urine pouch. The stool was
collected in preweighed diapers, the weight measured, and
the time of stool collection and consistency of each stool
recorded. Weight of stool and volume of urine in relation
to the child’s body weight were recorded every 6 hours.
Consistency of the stool was graded as watery, loose, semi-
loose, pasty, or formed, a grading system that had been used
in earlier ORS studies from this hospital (17). Initial stan-
dardization of the grading of stool consistency was reestab-
lished by the pediatricians. To avoid bias, the assessment of
consistency was performed by a study physician who was
blinded to the specific ORS administered to the child. The
time from first administration of ORS to the last unformed
stool was recorded as well as the time to the first formed stool.
Clinical decisions regarding management and need for
intravenous fluids were based solely on the state of hydration
of the child (as per the WHO guidelines) and were made by
the pediatrician on call or the attending pediatrician during
ward rounds, without reference to the type of ORS being
received by the child. Children were discharged from the
hospital when they had a formed stool. Body weight was
recorded at entry and after 4, 12, 24, and 48 hours. Informed
written consent was obtained from the parent. The study
design, patient information sheet, and consent form were
approved by the Ethics Committee (Institutional Review
Board) of the Christian Medical College.
The study was designed as a randomized trial that would
allow comparison between an established form of therapy
(G-ORS) and HAMS-ORS. The primary end points or
variables assessed for comparison were stool weight in the
first 24 hours, total stool weight until cessation of diarrhea,
and duration of diarrhea (defined as time from onset of oral
rehydration therapy until the last unformed stool). BTreatment
failure^ was defined as either the need for unscheduled
intravenous fluid therapy or the persistence of diarrhea beyond
72 hours, which was also a secondary end point. The study
ended in each individual patient either when there was a
formed stool or when there was treatment failure.
Treatment with G-ORS was chosen as the control group
because this is the ORS that has been tested most widely.
Although rice-ORS, in a number of different forms, is now
widely used, the inclusion of rice-ORS as an additional
treatment group would have resulted in the need to recruit a
substantially greater number of patients for the study. Data
were analyzed using GraphPad InStat Version 3.06 for
Windows. The continuous variables were expressed as means
with 95% confidence intervals. Significance of differences
between means of groups was measured using the Mann-
Whitney U test. Survival curves displaying time to termi-
nation of diarrhea and time to first formed stool were
compared using Breslow test, which provides greater weight
to the earlier part of the curves where more observations are
available. P values (2-tailed) were considered significant if
they were less than 0.05.
RESULTS
Based on sample size calculations derived from
another published study (21), we originally intended to
recruit 232 children into this study allowing for
dropouts. An interim analysis was performed with
blinded data for safety monitoring. Based on the mean
and SD of the fecal weight and duration of diarrhea for
the entire population of children with diarrhea, it was
calculated that the total number of children that would
be required to be recruited could be reduced to 160
cases with 80% power to detect a 25% difference in
duration of diarrhea between the 2 groups, whereas
approximately 200 cases would be needed to detect a
20% difference in stool volume with 80% power.
Because recruitment of patients into the study was
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slower than anticipated, the study was discontinued
before the initial targeted recruitment. The decision to
terminate the study was taken jointly by the 3 principal
investigators (P.R., B.S.R., and H.J.B.) as the number of
patients studied would allow conclusions to be drawn
regarding the effect of HAMS-ORS on the duration of
diarrhea, and the charts were reviewed for analysis at a
time when the 3 principal investigators were all present
in Vellore.
Of the 183 children that were recruited, 3 were
excluded because of withdrawal of consent and 2 because
of incomplete entry in the case record form (Fig. 1).
Unscheduled intravenous fluid therapy had a priori been
designated as an end point terminating the study. Fifteen
children (9 in G-ORS group and 6 in HAMS-ORS group)
required unscheduled intravenous fluids within 12 hours
of enrolment, and stool collection and recording was
terminated in these children before actual cessation of
diarrhea. Four children (2 in each study group) had
diarrhea persisting beyond 72 hours, and data were
available up to this point. Data from these children were
included in the intention-to-treat analysis until the time of
discontinuation at which point they became censored
observations. Nineteen children (8 in G-ORS group and 9
in HAMS-ORS group) had no stool output during the
initial 24 hours after entry into study, and they were
discharged at 24 hours. Data from these children were
included in intention-to-treat analysis with the assump-
tion that time from enrolment to last unformed stool was
0 hours and time from enrolment to first formed stool
was 24 hours. It is possible that those receiving an
unscheduled intravenous were the most ill and therefore
most likely to be followed for a long period without
terminating diarrhea or observing the first formed stool.
Hence, sensitivity analysis (ie, changing the censoring
time from their time of discontinuation to the full 72
hours’ follow-up) was done, which did not significantly
alter study conclusions.
The total amount of ORS consumed was similar in
both groups (Table 2) (P = NS). The mean stool output
in the first 24 hours was 31% lower in the HAMS-ORS
group compared with the G-ORS group, and this
difference showed a trend toward statistical significance
(Table 2). Total diarrheal stool output was 29% lower in
the HAMS-ORS group compared with the G-ORS
group, and again this difference showed a trend toward
statistical significance. Analysis of the subgroup of
children with rotavirus infection did not reveal any
significant difference in stool volume between the 2
treatment groups.
The time from enrolment into the study to the last
unformed stool was significantly shorter in children
FIG. 1. Flow chart of patients through the study and analysis.
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treated with HAMS-ORS than in children treated with
G-ORS (Table 2 and Fig. 2). The median time from
enrolment into study to the last unformed stool in
children receiving HAMS-ORS (6.75 hours) was sig-
nificantly lower than that in children receiving G-ORS
(12.8 hours) (P = 0.03). The median duration of time
from enrolment to the first formed stool was predictably
longer in both groups, but again was significantly lower
in the HAMS-ORS group (median, 18.25 hours)
compared with the G-ORS group (median, 21.5 hours)
(P = 0.04). Diarrhea lasting longer than 24 hours was
observed in 19 of 91 children randomized to G-ORS
compared with 13 of 87 children treated with HAMS-
ORS (P = NS). When the subgroup of children with
rotavirus infection was separately analyzed, the differ-
ence in duration of diarrhea between the 2 groups was
not statistically significant.
DISCUSSION
Improvement in the composition of ORS continues to
be a major research effort in the treatment of acute
diarrhea as there is no universal rehydration solution that
is equally effective in all types of diarrhea. Cholera and
other severe dehydrating diarrheas are associated with
high fecal losses of sodium and water, whereas rotavirus
and other diarrheas common in children have much
smaller losses of sodium. Any new ORS must be
established to decrease the duration of diarrhea as well
as reducing fecal fluid losses. It is expected that such
TABLE 2. Outcome Variables in Children Treated with HAMS-ORS Compared
with Those Treated with G-ORS
Variable HAMS-ORS G-ORS P
Total ORS consumed (mL/kg body weight)
Mean 79.6 87.3 NS
95% CI 67.1Y92.1 74.1Y100.4
Stool weight in initial 24 h (g/kg body weight)
Mean 35.5 51.3 0.07
95% CI 26.8Y44.3 40.0Y62.7
Total stool weight until last unformed stool
(g/kg body weight)
Mean 44.8 63.5 0.09
95% CI 31.7Y57.9 47.2Y79.9
Time from enrolment until last unformed stool (h)
Mean 6.75 12.8 0.03*
95% CI 4.27Y9.23 8.69Y16.91
Time from enrolment until first formed stool (h)
Mean 18.25 21.50 0.04*
95% CI 13.09Y23.41 17.26Y25.74
Unscheduled intravenous fluids 6 9 NS**
Diarrhea persisting beyond 72 h 2 2 NS**
NS indicates not significant.
P values shown are 2-tailed values using Mann-Whitney U test, *Breslow test, or **W2 test.
FIG. 2. Kaplan-Meier survival analysis related
to proportion of children continuing to have
diarrhea at different time intervals. The data
plotted are for time from entry into study
until last unformed stool and are shown for
178 children (91 G-ORS and 87 HAMS-
ORS). Details of the analysis are given in
the Results section.
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objective measures of efficacy will be translated into
increased acceptability by caregivers of patients with
diarrhea. The present study demonstrates that starch that
is relatively resistant to amylase digestion (or resistant
starch) significantly reduced the duration of diarrhea in
children with acute diarrhea that was predominantly
because of causes other than cholera. The primary
outcomes that were evaluated were whether the new
ORS reduced stool volume and duration of diarrhea
compared with the standard G-ORS, attributes that we
believed any new ORS must possess. The secondary
outcome was the need for unscheduled intravenous fluid
therapy, which indicates the therapeutic efficacy of the
test-ORS compared with the standard-ORS. The use of
amylase-resistant starch was associated with a trend to
lower stool weight during the first 24 hours.
Despite its efficacy in correcting dehydration and
preventing mortality, ORS has not achieved the wide-
spread use that was initially expected. Although this
may be due in considerable part to lack of knowledge
or appreciation of the effects of ORS, caregivers in the
community have been reluctant to use ORS when it
does not palpably reduce diarrhea (22). The G-ORS is
associated with persistence of diarrhea during ORS
administration, whereas hypo-osmolar ORS may reduce
diarrhea to some extent. Green bananas and pectin have
been shown to reduce duration of diarrheal illness and
hasten recovery in children with persistent diarrhea in
Bangladesh (23). Green bananas contain amylase-resistant
starch, and the assumption is that the starch is fermented
to SCFAs in the colon, which, besides salvaging sodium
and water from the colon, also enhance mucosal function
and recovery. Amylase-resistant starch is poorly digested
in the small intestine, but is fermented in the colon to
SCFAs by the luminal bacterial flora. SCFAs increase Na
absorption from the secreting colon. The model of SCFA
stimulation of sodium absorption requires a Na-H ex-
change, similar to that for HCO3 stimulation of Na ab-
sorption. Although cAMP inhibits HCO3-dependent
sodium absorption as a result of inhibition of Na-H
exchange, SCFA-dependent sodium absorption is not in-
hibited by cAMP. This apparent paradox is likely
explained by the observation that SCFA-dependent sodium
absorption may occur via either NHE-2 or NHE-3,
whereas HCO3-dependent sodium absorption is only de-
pendent on NHE-3. Cyclic nucleotides inhibit the NHE-3
isoform but increase NHE-2 isoform activity. In addition,
it has been shown that SCFAs inhibit chloride secretion
(the primary driving force for fluid secretion in cholera and
other secretory diarrhea) in the colon. Amylase-resistant
starch had earlier been shown to reduce significantly both
fluid losses and the duration of diarrhea in adults with
cholera (17). The present study extends this earlier
observation and shows that amylase-resistant starch is also
useful in the treatment of noncholera diarrhea in children.
This reduction in the duration of diarrhea occurred
despite early refeeding of children in both treatment
groups. It is clear from prior studies that early refeeding
significantly shortens the duration of diarrhea (5,6).
Refeeding introduces complex carbohydrates in children
ingesting a normal diet and thus provides substrate for
SCFA generation in the colon. Starch in the colon is a
substrate that is rapidly fermented to SCFAs and
preferentially fermented to butyrate. It is, therefore,
likely that the additional benefit provided by amylase-
resistant starch is because of increased generation of
SCFAs, possibly butyrate. A recent multicenter study
carried out by ESPGHAN in 8 centers enrolled 144 boys
with acute diarrhea and examined the addition of a
mixture of nondigestible carbohydrates to ORS on the
course of diarrhea. In these children, the addition of a
mixture of nondigestible carbohydrates (soy polysac-
charide, cellulose, gum arabic, fructo-oligosaccharide,
inulin, and a small amount of resistant starch) to ORS
did not provide any significant reduction of diarrhea
duration, fecal volume, or unscheduled intravenous
fluid therapy (19). It is likely that this lack of benefit
was because of the nature of the specific carbohydrates
used and/or to the low concentration of nondigestible
carbohydrate administered. In that study 10 g/L of
unabsorbed carbohydrate was administered, compared
with approximately 25 g/L of resistant starch (expected
to enter the colon), which was administered in the
present study. In another study of 150 male children
with acute diarrhea, addition of partially hydrolyzed
guar gum significantly reduced duration of diarrhea,
and reduced stool volume on day 7 of diarrhea (18).
These somewhat contrary observations suggest that
the concentration of nondigestible carbohydrate as well
as the absolute amount of nondigestible carbohydrate
could be important in determining its effect on the
duration of diarrhea.
The use of reduced osmolarity ORS has been in wide
practice in the past few years largely because some
children developed hypernatremia when receiving
conventional G-ORS. This study used the old WHO
ORS as the reference treatment because this was the
recommended therapy at the time of the start of the trial.
As a result of studies performed in several centers
worldwide, the World Health Organization revised its
recommendation for ORS composition in mid-2002 and
now recommends a lower sodium and glucose concen-
tration for the treatment of diarrhea (24,25). In countries
where cholera is common, it is expected that the use
of a single or universal reduced osmolarity ORS for all
kinds of diarrhea will likely result in problems related
to hyponatremia (26). We have shown in whole gut
perfusion studies in animals (unpublished observations)
that amylase-resistant starch significantly enhances
sodium absorption from a hypo-osmolar ORS. The
present study suggests that clinical trials in adults and
children with diarrhea to determine the effect of adding
amylase-resistant starch to reduced osmolarity ORS
would be appropriate.
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